Macular hole formation following photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide.
Iwama
Daisuke
D
Ooto
Sotaro
S
Tsujikawa
Akitaka
A
Yamashiro
Kenji
K
Yoshimura
Nagahisa
N
D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002829:Choroid / Q000098:blood supply; D015862:Choroid Diseases / Q000188:drug therapy; D003131:Combined Modality Therapy; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D007267:Injections; D008297:Male; D016491:Peripheral Vascular Diseases / Q000188:drug therapy; D010778:Photochemotherapy / Q000009:adverse effects*; D012167:Retinal Perforations / Q000209:etiology*; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000009:adverse effects*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide